Novigenix is a Swiss precision medicine company specialized in ImmunoTranscriptomic solutions for the detection of disease, therapy optimization, and disease recurrence monitoring to improve disease management and patient outcomes. The Novigenix proprietary LITOseek platform is optimized for mapping the response of the immune system to onset and progression of disease by integrating patient multi-omics data, advanced Machine Learning, and artificial intelligence approaches, to provide actionable insights and precision solutions for optimization of patient’s therapeutic journey. Our product pipeline currently includes patient stratification solutions in the field of Immuno-Oncology, Colorectal Cancer early detection and recurrence monitoring, and therapy optimization solutions for management of cancer patients. Novigenix provides services to Pharma and Biotech customers by leveraging the proprietary LITOseek data analytics and patient clinical data platform to deliver previously unknown insights into the immune system, and develop ImmunoTranscriptomic solutions with actionable biomarkers for optimization of new therapeutic modalities. Specialties Precision Medicine solutions in oncology and other indications, ImmunoTranscriptomics, Machine Learning and Artificial Intelligence, clinical development of multi-omics biomarkers, standardized RNAseq platform and analytic pipelines, product development for In-vitro Diagnostics and Liquid Biopsy solutions.
Location: Switzerland, Vaud, Epalinges
Employees: 11-50
Total raised: $21.11M
Founded date: 2014
Funding Rounds 2
Date | Series | Amount | Investors |
03.12.2022 | Series B | $20M | - |
21.01.2020 | Grant | $1.11M | - |
Mentions in press and media 17
Date | Title | Description |
03.10.2024 | EU funds AI-driven medical projects powered by Swiss startups | The MYeloid SIGNATUREs (MY-SIGNATURE) project led by Novigenix, a leader in AI-driven healthcare solutions, aims to address the urgent need for robust biomarkers to optimize treatment and overcome resistance to current therapies for prosta... |
05.06.2024 | Outstanding startup solutions receive prizes | ImpactLab, the first incubator at the FHNW School of Business, offers student entrepreneurs a stage to present their business ideas to the jury to secure a place in the Talent Pitch competition in Zurich. At the Elevator Pitching Context, ... |
31.05.2024 | Swiss life science startups headed for San Diego | The BIO International Convention 2024, taking place in San Diego from 3 to 6 June, is the largest global biotechnology event with over 20,000 industry leaders from around the world attending. The target group includes representatives from ... |
22.05.2024 | "EMBRACING INTERNATIONAL ALLIANCES" SWISS BIOTECH INNOVATION ON DISPLAY AT THE BIO 2024 INTERNATIONAL CONVENTION IN SAN DIEGO JUNE 3-6, 2024 | ZURICH, May 22, 2024 /PRNewswire/ -- Swiss life science innovation will again be on display at the BIO 2024 convention in San Diego. Switzerland Global Enterprise will present 41 leading Swiss biotech stars at the SWISS BIOTECH pavilion dem... |
07.03.2024 | Europe Colorectal Cancer Screening and Diagnostic Market Analysis and Forecast 2023-2033, Featuring Key Players Epigenomics, Mainz Biomed and Novigenix | - |
02.12.2022 | Novigenix Holds First Closing of $20M Series B Funding | Novigenix, a Lausanne, Switzerland-based biotech company focused on Immuno-Transcriptomic oncology solutions, raised $20M in Series B funding. The backers were not disclosed. The company intends to use the funds to fast track the clinical v... |
16.11.2022 | Novigenix attracts funding to advance precision oncology solutions | |
23.07.2021 | A global stage for Swiss innovators | |
11.03.2021 | New appointments at life sciences startups | Versantis AG, a clinical-stage company developing novel therapies for orphan liver diseases, appointed seasoned pharmaceutical executive Christopher Seaton to its Board of Directors. Seaton has extensive business development expertise, with... |
11.03.2021 | New appointments at life sciences startups |
Show more